Evidence map›Paper›PMID 39717580›Full record

ArticleHeliyon2024

Evaluation of the Vitros® Anti-T. cruzi assay for its incorporation into the

Miriam Campos-Ruiz, Jun Hao Wang-Wang, Belén Rivaya, Beatriz Rodriguez-Ponga, Noelia López, Victoria González, Pere-Joan Cardona, Gema Fernández-Rivas

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Miriam Campos-RuizMicrobiology Department, Clinical Laboratory North Metropolitan Area, Germans Trias I Pujol University Hospital, 08916 Badalona, Spain.
Jun Hao Wang-WangMicrobiology Department, Clinical Laboratory North Metropolitan Area, Germans Trias I Pujol University Hospital, 08916 Badalona, Spain.
Belén RivayaMicrobiology Department, Clinical Laboratory North Metropolitan Area, Germans Trias I Pujol University Hospital, 08916 Badalona, Spain.
Beatriz Rodriguez-PongaMicrobiology Department, Clinical Laboratory North Metropolitan Area, Germans Trias I Pujol University Hospital, 08916 Badalona, Spain.
Noelia LópezMicrobiology Department, Clinical Laboratory North Metropolitan Area, Germans Trias I Pujol University Hospital, 08916 Badalona, Spain.
Victoria GonzálezMicrobiology Department, Clinical Laboratory North Metropolitan Area, Germans Trias I Pujol University Hospital, 08916 Badalona, Spain.
Pere-Joan CardonaMicrobiology Department, Clinical Laboratory North Metropolitan Area, Germans Trias I Pujol University Hospital, 08916 Badalona, Spain.
Gema Fernández-RivasMicrobiology Department, Clinical Laboratory North Metropolitan Area, Germans Trias I Pujol University Hospital, 08916 Badalona, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and objective: Serological screening for Chagas disease (CD) in Latin American adults living in Europe is a cost-effective strategy for transmission prevention. The World Health Organization recommends two different serological tests including native and recombinant antigens for IgG detection. In Spain, most commercialized native tests require manual processing. We aimed to evaluate the sensitivity and specificity of the automated Vitros® Anti-T. cruzi native antigen-based test. Methods: A total of 556 serum samples were tested using two different tests: 1) our reference assay, a chemiluminescence immunoassay employing a recombinant multi-antigen protein (Liaison® XL Murex Chagas); 2) a chemiluminescence immunoassay with native antigen (Vitros® Anti-T. cruzi assay). Additionally, 180 samples were also processed by a manual indirect immunofluorescent assay (Chagas IFA). Sensibility, specificity and kappa index were calculated. Results: Vitros® showed a kappa index of 0.94 (IC 95 %: 0.86-1.03) compared to Liaison® XL with a sensitivity of 93.6 % and specificity of 99.5 %. Compared to IFA, Vitros® showed a kappa index of 0.61 (IC 95 %: 0.47-0.76), sensitivity of 97.5 % and specificity of 70.37 %. Discrepant results were obtained mainly in treated patients. Conclusions: The Vitros® Anti-T. cruzi assay showed potential for implementation as an automated serological screening test, enhancing the diagnostic process in high-throughput microbiology laboratories.

Indexed as

Chagas diseaseNative antigenSerological diagnosisTrypanosoma cruzi

Identifiers

PMID39717580
PMCPMC11664266

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.